Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation
Background: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for sever...
Main Authors: | Gregor Duwe, Lukas Müller, Christian Ruckes, Nikita Dhruva Fischer, Lisa Johanna Frey, Jan Hendrik Börner, Niklas Rölz, Maximilian Haack, Peter Sparwasser, Tobias Jorg, Christopher C. M. Neumann, Igor Tsaur, Thomas Höfner, Axel Haferkamp, Felix Hahn, Rene Mager, Maximilian Peter Brandt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/9/2482 |
Similar Items
-
Solitary cardiac metastasis of urothelial carcinoma of the urinary bladder with squamous cell differentiation – a rare manifestation
by: Gregor Duwe, et al.
Published: (2023-01-01) -
Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma
by: Chia-Chun Tsai, et al.
Published: (2013-04-01) -
Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
by: Meng Yang, et al.
Published: (2024-02-01) -
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
by: Kazuma Sugimoto, et al.
Published: (2022-11-01) -
High–Normal Preoperative Potassium Level Is Associated with Reduced 30–Day Morbidity and Shorter Hospital Stay after Radical Cystectomy
by: Hendrik Borgmann, et al.
Published: (2022-02-01)